Journal Image
Current Pharmaceutical Design
ISSN (Print): 1381-6128
ISSN (Online): 1873-4286
DOI: 10.2174/138161211796957445      Price:  $58

Nutrapharmacology of Tocotrienols for Metabolic Syndrome

Author(s): Wong Weng-Yew and Lindsay Brown
Pages 2206-2214 (9)
Metabolic syndrome is defined as a set of health risk factors that are associated with an increased chance of cardiovascular diseases and type 2 diabetes. These include abdominal obesity, hyperglycemia, impaired glucose tolerance, dyslipidemia, and hypertension. Interventions in metabolic syndrome include lifestyle interventions such as a healthy diet using functional foods together with increased physical activity to induce weight loss as the first aim of treatment. Nutraceuticals such as tocotrienols and tocopherols as members of the vitamin E family may be more targeted interventions. This review evaluates the effects of tocotrienols on the risk factors of metabolic syndrome using data from human, animal and in vitro studies. Tocotrienols improved lipid profiles and reduced atherosclerotic lesions, decreased blood glucose and glycated hemoglobin concentrations, normalized blood pressure, and inhibited adipogenesis. The differences in responses between tocopherols and tocotrienols in preventing obesity, diabetes, hypertension, artherosclerosis, ischemia, and inflammation suggest that different receptors or signaling mechanisms may be involved.
Metabolic syndrome, tocotrienols, tocopherols, diabetes, hypertension, atherosclerosis, adipogenesis, artherosclarosis, chylomicrons, hepatocytes
Department of Biological and Physical Sciences, Faculty of Sciences, University of Southern Queensland, Toowoomba, QLD 4350, Australia.